文献速递骨软组织肉瘤与黑色素瘤

NALIRI‑VT 方案治疗复发难治性尤文肉瘤的1a/b期研究

An open-label, two-cohort, phase 1a/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma.
PubMed 文献 · Eur J Cancer · 2026-04-12

该开放标签、非随机、两队列1a/b期研究纳入复发或难治性尤文肉瘤儿童与成人,采用3+3剂量递增确定推荐II期剂量(RP2D),并评估安全性与初步疗效。RP2D为NALIRI 35 mg/m²,两队列确认客观缓解率均为54.5%,毒性以血液学为主且总体可控。

要点

  • RP2D为NALIRI 35 mg/m²,联合长春新碱与替莫唑胺每21天给药。
  • RP2D下儿童与成人确认客观缓解率均为54.5%,临床获益率分别为81.8%与63.6%。
  • 3/4级毒性以血液学为主,常见不良反应包括厌食、乏力、恶心呕吐、疼痛与腹泻。

核心结论

  • NALIRI‑VT在晚期尤文肉瘤中毒性可控并显示有前景的抗肿瘤活性,支持进一步开展II期研究。

研究设计与样本

  • 开放标签、非随机、两队列、两阶段1a/b期研究,儿童为A队列、成人为B队列,入组复发或难治性尤文肉瘤患者。
  • 1a期采用3+3剂量递增,NALIRI每周输注,起始25 mg/m²(1级),递增至30、35、40 mg/m²(2–4级);长春新碱1.5 mg/m²(单次最大2 mg,第1天静注)与替莫唑胺100 mg/m²(第1–5天口服)每21天给药。
  • 共入组24例儿童和24例成人(1a期16例与19例;1b期新增8例与5例)。

主要发现

  • 1–2级未发生剂量限制性毒性(DLT);3级DLT为儿童0/3、成人1/6;4级两队列各2/6出现DLT。
  • RP2D为3级(NALIRI 35 mg/m²),RP2D下纳入11例儿童和11例成人。
  • RP2D下两队列确认客观缓解率均为54.5%,临床获益率儿童81.8%、成人63.6%。
  • 中位无进展生存期3.6个月(95%CI 2.7–NA),中位总生存期12.5个月(95%CI 7.9–NA)。
  • 3/4级毒性主要为血液学毒性;常见不良事件包括厌食、乏力、恶心呕吐、疼痛和腹泻。

关键数值与推荐

  • NALIRI推荐II期剂量为35 mg/m²(3级),每周输注。
  • 长春新碱1.5 mg/m²(单次最大2 mg)第1天静注,替莫唑胺100 mg/m²第1–5天口服,每21天为一周期。

临床怎么用

  • 对复发或难治性尤文肉瘤儿童及成人,可考虑以NALIRI 35 mg/m²联合长春新碱与替莫唑胺作为候选方案。
  • 治疗期间需重点监测血液学毒性及厌食、乏力、恶心呕吐、疼痛、腹泻等不良事件。

局限性

  • 中位无进展生存期与总生存期的95%CI上限未达到(NA),生存数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the recommended phase II dose (RP2D), safety, and preliminary efficiency of liposomal irinotecan combined with vincristine and temozolomide (NALIRI-VT) in children and adult with relapsed/refractory Ewing sarcoma. PATIENTS AND METHODS: This open-label, non-randomized, two-cohort, two-part phase Ia/b study enrolled pediatric(Cohort A) and adults(Cohort B) with relapsed or refractory Ewing sarcoma. In phase 1a, NALIRI was administered as a weekly infusion using 3 + 3 dose-escalation design staring at 25 mg/m2 (level 1) and escalating to 30, 35, and 40 mg/m2 (levels 2-4). Vincristine (1.5 mg/m² Dmax 2 mg D1i.v.) and temozolomide (100 mg/m² D1-5 p.o.) were administered every 21 days. Primary objectives were safety and tolerability. The phase 1b portion expanded patient enrollment at the established recommended phase II dose (RP2D) to further evaluate safety and preliminary efficacy. RESULTS: From April 15 to December 30, 2024, 24 children and 24 adults were enrolled (phase 1a: 16 and 19; phase 1b: +8 and +5, respectively). No dose-limiting toxicity (DLT) occurred at levels 1-2. At level 3, DLTs occurred in 0/3 children and 1/6 adults. At level 4, DLTs were observed in 2/6 patients in each cohorts. The RP2D was level 3 (NALIRI 35 mg/m²). At RP2D (11 children and 11 adults), confirmed objective response was 54.5% in both cohorts; clinical benefit rate was 81.8%(children) and 63.6%(adults). Median progression-free survival was 3.6 (95% confidence interval [CI], 2.7-NA) months, and median overall survival was 12.5 (95% CI, 7.9-NA) months. Grade 3/4 toxicities were mainly hematologic; common adverse events included anorexia, fatigue, nausea/vomiting, pain, and diarrhea. CONCLUSIONS: NALIRI-VT shows manageable toxicity and promising activity in advanced Ewing sarcoma, justifying further investigation in phase II trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Xu J, Yu Y, et al. An open-label, two-cohort, phase 1a/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma. Eur J Cancer. 2026. PMID: 42019227. doi:10.1016/j.ejca.2026.116743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。